4 Weeks Treatment With Empagliflozin (BI 10773) in Japanese Type 2 Diabetic Patients (T2DM)

Exclusion Criteria

• •1. Antidiabetic treatment with insulin or glitazones within 3 months before obtaining informed consent or with more than 1 oral hypoglycaemic agent at the time of informed consent
• •2. Fasted blood glucose of \>240 mg/dL (\>13.3 mmol/L) or a randomly determined blood glucose level of \>400 mg/dL (22.2 mmol/L) on 2 consecutive days during wash-out period.
• •3. Myocardial infarction, stroke, or transient ischaemic attack within 6 months before informed consent.
• •4. Clinically relevant concomitant diseases other than T2DM, hyperlipidaemia, and medically treated hypertension before the first administration such as
• •* Renal insufficiency (calculated estimated glomerular filtration rate \<60)
• •* Cardiac insufficiency of New York Heart Association (NYHA) II-IV or other known cardiovascular diseases including hypertension of \>160/95 mmHg,
• •* Neurological disorders (such as epilepsy) or psychiatric disorders
• •* Acute or clinically relevant chronic infections (e.g., human immunodeficiency virus, hepatitis, repeated urogenital infections)
• •* Any gastrointestinal, hepatic, respiratory, endocrine, or immunological disorder
• •5. Patients under treatment with any concomitant medication except for the following drugs at the time of informed consent.:
• •* Statins.
• •* Antihypertensives (diuretics not allowed)
• •* alpha-Blockers for benign prostate hypertrophy
• •* Occasional use of acetylsalicylic acid, ibuprofen, or paracetamol